Skip to main
MRUS

Merus (MRUS) Stock Forecast & Price Target

Merus (MRUS) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 13%
Buy 13%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

Merus NV has a promising outlook due to Genmab's announcement of a $97/share acquisition offer, which represents a 41% premium on its closing share price and values the company at approximately $8 billion. The merger is expected to enhance Genmab's late-stage pipeline, particularly with the addition of Merus' petosemtamab, a bispecific antibody that has received two FDA Breakthrough Therapy Designations and is projected to generate at least $1 billion in annual sales by 2029. Moreover, the strategic alignment highlights the potential for growth in proprietary launches by 2027, further reinforcing Merus's positive financial trajectory within the immuno-oncology landscape.

Bears say

The financial outlook for Merus NV is negatively impacted by the recent proposed acquisition by Genmab, which is valued at approximately $8 billion. The downgrade from a "Best Idea" designation to Neutral reflects concerns about the acquisition's implications on Merus's future growth potential, particularly as Genmab intends to finance this transaction with a substantial amount of non-convertible debt. Additionally, the reduced price target from $109 to $97 per share signals a pessimistic view on the likelihood of higher bids materializing and the overall financial stability of Merus in the long term.

Merus (MRUS) has been analyzed by 15 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 13% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merus (MRUS) Forecast

Analysts have given Merus (MRUS) a Hold based on their latest research and market trends.

According to 15 analysts, Merus (MRUS) has a Hold consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merus (MRUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.